Does Pfizer's Latest News Snatch a Big Market Opportunity Away From Moderna?
Pfizer (NYSE: PFE) just scored another first. The U.S. Food and Drug Administration (FDA) granted it authorization for the use of its coronavirus vaccine in a new age group -- 12 through 15. In December, Pfizer became the first company to win Emergency Use Authorization (EUA) for a coronavirus vaccine. That covered individuals ages 16 and older.
A Centers for Disease Control and Prevention (CDC) panel meets today to discuss the expansion of use. Once the CDC issues its recommendation, healthcare facilities may start vaccinating younger teens. Of course, this is great news for Pfizer. But what does this mean for fellow market leader Moderna (NASDAQ: MRNA)? The biotech company also is aiming to vaccinate teens. Let's see where things stand.
Image source: Getty Images.
Source Fool.com
